Looking into Unisys’s Return on Capital Employed

Pulled from Benzinga Pro data Unisys (NYSE:UIS) showed a loss in earnings since Q1, totaling $40.80 million. Sales, on the other hand, increased by 1.47% to $517.30 million during Q2.

Pulled from Benzinga Pro data Unisys (NYSE:UIS) showed a loss in earnings since Q1, totaling $40.80 million. Sales, on the other hand, increased by 1.47% to $517.30 million during Q2. In Q1, Unisys earned $43.60 million and total sales reached $509.80 million.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company’s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Unisys posted an ROCE of -0.15%.

Keep in mind, while ROCE is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Unisys is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.

For Unisys, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.

Upcoming Earnings Estimate

Unisys reported Q2 earnings per share at $0.68/share, which beat analyst predictions of $0.33/share.

Total
0
Shares
Related Posts
Read More

Recap: AtriCure Q4 Earnings

AtriCure (NASDAQ:ATRC) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by 3.45%, reporting an EPS of $-0.3 versus an estimate of $-0.29.

ATRC